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Summary The antibiotic drug novobiocin was evaluated for its anti-tumour properties in B16 melanoma
cells. Novobiocin is shown to inhibit melanoma B16 cell proliferation. The anti-proliferative effect was
gradually reversible upon removal of novobiocin from the culture medium. Growth inhibition by novobiocin
was accompanied by phenotypic alterations, that included morphological changes, lipid accumulation and
marked increases in the activities of NADPH cytochrome c reductase and y glutamyl transpeptidase. In vivo
administration of repeated i.p. doses of novobiocin, to mice implanted with B16 melanoma cells resulted in
growth retardation. The combined treatment of the B16 melanoma cells with novobiocin and other chemical
inducers of differentiation was examined in a cell growth assay. Novobiocin and sodium butyrate inhibited cell
growth in a near additive manner, while combination of novobiocin with the GTP-depleting agents, tiazofurin
or mycophenolic acid resulted in a synergistic decrease in cell growth. Our results support the contention
further that novobiocin and other differentiating agents might be of potential value in melanoma therapy.
Melanoma is known to be a chemotherapy-resistant cancer.
Previous studies from our laboratory have focussed on the
evaluation of the effects of chemical inducers of
differentiation on mouse and human melanoma cells. These
studies were aimed at the discovery of modalities that might
modulate the cells to express a more differentiated and
benign phenotype. We have shown that several agents, belon-
ging to different chemical groups, such as dimethylsulfoxide,
dimethylthiourea, sodium butyrate, histidinol and 8-hydroxy-
quinoline inhibit melanoma cell proliferation and induce
differentiated characteristics in the cells (Nordenberg et al.,
1985; 1986; 1987; 1989; 1990). However, the compounds
tested so far did not seem to be suitable for immediate
clinical evaluation.
Novobiocin (Figure 1), a coumermycin antibiotic drug,
which inhibits prokaryotic and eukaryotic DNA replication
seemed to be an interesting candidate for evaluation as an
anti-tumour differentiating agent in melanoma. The best
known effect of novobiocin is its inhibition of topoisomerase
II activity, due to interference with the ATPase subunits of
the enzyme (Gellert, 1982). Novobiocin was recently shown
to induce cell differentiation in several leukaemic cell lines
(Constantinou et al., 1989; Rappa et al., 1990). Induction of
differentiation in the HL-60 leukaemic cell line was attributed
to inhibition of topoisomerase II activity (Constantinou et
al., 1989). Novobiocin was also reported to induce mitochon-
drial damage, leading to a decrease in the ATP/ADP ratio in
Hela cells (Downes et al., 1985). We have recently shown
that inhibition of B16 melanoma cell growth and induction
of differentiated features by dimethylthiourea was at least
partially mediated by a decrease in ATP content (Fux et al.,
1991). Recent reports have also focussed interest on the
anti-tumour properties of novobiocin. It was shown to exert
in vitro and in vivo synergistic anti-tumour effects with alky-
lating agents (Eder et al., 1987; 1989), to enhance cisplatinum
cytoxicity (Eder et al., 1987; 1988) and to increase sensitivity
of ovarian cancer cells to hyperthermia (Warters et al., 1988).
Recently, a phase I trial of novobiocin in combination with
cyclophosphamide has been conducted in patients with
various disseminated malignancies (Eder et al., 1991). Novo-
biocin was well tolerated in patients receiving cyclophospha-
mide and blood levels achieved were in the drug-potentiating
range. The use of chemical inducers of differentiation in solid
tumour cells might modify the cells in a way that renders
them more susceptible to the effects of another differentiating
agent. This was demonstrated by several investigators, using
sodium butyrate in combination with 5'azacytidine, 1,25
dihydroxy vitamin D or retinoic acid (Jahangeer et al., 1982;
Toshiyuki et al., 1984; Kyritsis et al., 1985).
The aim of this study was to evaluate the effects of
novobiocin on melanoma cell growth and differentiation and
to examine its interaction with other differentiating agents.
Materials and methods
Reagents for tissue culture were purchased from Biol. Indus-
tries, Novobiocin and reagents for enzyme assays were ob-
tained from Sigma Chem. Comp.
C57/B1 mice (4-6 weeks old), fed ad libitum, from the
animal unit of the Beilinson Medical Center were used.
Cell line
B16 FlO murine melanoma cells were cultured in RPMI
1640, supplemented with 10% foetal calf serum, antibiotics
and the anti-mycoplasma agent PPLO from Gibco Comp. as
previously described (Nordenberg et al., 1986). For growth
experiments, cells (4 x 104 1.5 ml-') were incubated in tissue
culture dishes (3 cm) with or without different concentrations
of novobiocin. Cell number was determined by counting the
cells in a Coulter counter following detachment of the cells
with EDTA (1 mM).
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Figure 1 Chemical structure of novobiocin.
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Determination ofphenotypic alterations
For demenstration of cell morphology and lipid droplets,
cells were incubated in the presence and absence of novo-
biocin (100gM) in tissue culture plates for 72 h. Cells were
fixed with formol-calcium. Following fixation cells were
stained by the oil red 0 method (Pearse, 1968) and visualised
by light microscopy.
For determination of enzyme activities, cells (7 x 105) in
10 ml of culture medium were incubated for 72 h in the
absence or presence of novobiocin (100gM). NADPH cyto-
chrome c reductase and I glutamyl transpeptidase activities
were determined spectrophotometrically, as previously des-
cribed (Nordenberg et al., 1987). NADPH cytochrome c
reductase activity was expressed as nmoles acceptor reduced
h-' mg-' DNA.
j Glutamyl transpeptidase activity was expressed as gLmoles
product formed h-' mg ' DNA. DNA was measured by
the fluorometric method described by Labarca and Paigen
(1980).
Tumour cell inoculation andsystemic administration of
novobiocin
5 x 104 B16 melanoma cells were s.c. inoculated on the dor-
sum of the mice as previously described (Nordenberg et al.,
1985). Tumour growth was followed by measuring the
tumour diameters in three dimensions, using calipers and
tumour volume was calculated as previously described (Nor-
denberg et al., 1985). 0.3 ml PBS with, or without novobiocin
(150 mg Kg-') were injected i.p. according the following
schedule: three times daily for the first 2 days after tumour
cell inoculation and then twice daily for additional 10 days.
(The number of daily novobiocin doses was decreased from
three to two times daily because the mice suffered from
diarrhoea).
Preparation ofshort-term B16 cell culturesfrom tumour tissue
Tumour tissue, which is encapsulated and very fluid was
collected. Cells were disrupted mechanically under sterile
conditions and filtered through gauze. The cell suspension
was dissolved in RPMI 1640, containing 10% foetal calf
serum and incubated in a humidified atmosphere at 37°C in a
5% CO2 and 95% air atmosphere. After 48 h medium was
replaced. 24-48 h later, the cells were detached and replated
for additional 48 h and then used for growth experiments. It
should be noted that the cells from the tumour tissue were
heavily pigmented, while cells growing for many generations
as a cell line in culture were poorly pigmented.
Combined treatment ofB16 cells with novobiocin and other
differentiating agents
Cells (2 x 104) were incubated in 0.5 ml growth medium in
multiwell plates (15 mm) plates for 72 h in the presence or
absence of novobiocin, sodium butyrate, tiazofurin or myco-
phenolic acid alone or in combinations at the concentrations
indicated in the figures. Cells were detached and counted as
described above.
Statistical analysis ofdata
Paired t-test was used for evaluation of significance of the
effects on enzyme activities and unpaired t-test was used for
the in vivo studies.
The expected value for additive interaction of novobiocin
with sodium butyrate or tiazofurin was calculated by using
the formula described by Ravid et al. (1990) F (A + B) = 1-
(1-FA) (1-FB) where FA and FB are the fractions of the
proliferating cells inhibited by agents A and B. This calcula-
tion is based on the assumptions of Valeriote et al. (1975).
The statistical significance of the synergistic interaction was
assessed by the nonparametric sign test.
Results
Anti-proliferative effects ofnovobiocin in vitro and in vivo
The effect of novobiocin on the proliferation of B16 melan-
oma cells grown for many generations in cell culture was
examined by plating the cells in the absence and presence of
various concentrations of novobiocin for 48 and 96 h. The
number of untreated cells increased about 23 fold during the
96 h incubation period. Novobiocin induced a concentration
dependent decrease in cell number as is shown in Figure 2.
At 48 h 150tLM novobiocin decreased cell number beyond
initial number plated, suggesting that this concentration led
to an initial reduction in cell viability. However, proliferation
of remaining cells did not stop as can be seen from the 96 h
data. The cells that were counted after 96 h did not detach
and were 95% viable as assessed by the trypan blue exclusion
test.
Effects of differentiating agents on solid tumour cell lines
are known to be reversible. In order to examine whether
novobiocin-treated cells resume growth following removal of
novobiocin from the culture medium cells were replated with-
out novobiocin for different time periods. The results show
that 4 days following removal of novobiocin from the
medium, its growth inhibitory effect was still maintained
(Figure 3a). However, growing the cells for 11 days in
novobiocin-free medium, resulted in restoration of normal
growth rate (Figure 3b).
The sensitivity of cells to growth-inhibition by novobiocin
in short term cultures prepared from fresh melanoma tu-
mours was compared to that of the cells grown as a contin-
uous cell line. Both cell types were found to be equally
sensitive to growth inhibition by novobiocin (Results not
shown). This finding encouraged us to examine the effect of
in vivo application of novobiocin to mice inoculated with B16
melanoma cells. Mice inoculated s.c. with 5 x 104 viable B16
cells developed visible spherical tumours on their dorsum
within 10-12 days after inoculation, leading to death of the
mice within 20-30 days. The results depicted in Figure 4
show that repeated daily i.p. injections of novobiocin resulted
in delayed tumour growth in the novobiocin-treated group.
Measurements of tumour volume were stopped on day 20,
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Figure 2 The effect of novobiocin on B16 F0 melanoma cell
proliferation. Cells were incubated and counted as described in
methods. Values are means ± s.d. for three plates for each
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since three out of eight mice in the untreated group were
already dead at this time. Less aggressive treatment sched-
ules, for example application of single daily injection of
novobiocin for 5 days, were tried but failed to induce a delay
in tumour growth.
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Figure 3 Cell growth of B16 melanoma following removal of
novobiocin from the medium. a, 2 x 105 untreated or novobiocin
pre-treated (72h) cells were incubated in 5ml novobiocin-free
medium for 96 h. Cells were detached and counted as described
in the methods. b, Untreated or novobiocin pre-treated (72h)
cells were grown in novobiocin-free medium for 7 days. Cells
were replated at 2 x 105 cells in 5 ml novobiocin free-medium, for
additional 96 h. Cells were detached and counted as described in
the methods.
Phenotypic alterations inducedby novobiocin
The anti-proliferative effects ofnovobiocin were accompanied
by phenotypic alterations, that resembled those induced by
other chemical inducers ofdifferentiation. Novobiocin altered
cell morphology. The untreated cells were spindle shaped,
whereas the treated cells were flat, spread with elongated
appendages and seemed to be enlarged. Novobiocin-
treatment induced the accumulation of lipid droplets in the
cytoplasm (Figure 5). Incubation of the B16 cells with
novobiocin for 72 h resulted in a marked enhancement of the
activities of the plasma membrane-bound enzyme y glutamyl
transpeptidase and of the endoplasmic reticulum marker
enzyme NADPH cytochrome c reductase (Table I).
Combinedanti-proliferative effects ofnovobiocin and other
differentiating agents
The effect on cell growth of combined treatment of B16 cells
with novobiocin and other chemical inducers of
differentiation was examined. Incubation of the B16 cells
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Figure 4 In vivo anti-tumour activity of novobiocin. Inoculation
of cells and calculation of tumour volumes was described in
methods. Values are mean volumes ± s.e. for eight mice in each
group. Untreated vs novobiocin-treated at days 16 and 18
(P<0.01) and at day 20 (P<0.001).
b
Figure 5 Morphological appearance and lipid content of un-
treated and novobiocin-treated B16 FIO cells. a, Untreated cells
x 200. b, 72 h Novobiocin (1I00tM)-treated cells. x 200.
Table I The effect of novobiocin on the activities of NADPH
cytochrome c reductase and y glutamyl transpeptidase
Treatment NADPH cytochrome c reductase Zy glutamyl transpeptidase
nmoles mgDNA ' h-'1tmoles mgDNA ' h '
Untreated 6.18 0.12 4.82 0.19
Novobiocin (100!1m) 22.90± 0.66a 27.62± 1.24a
Values are means ± s.e. offive independent experiments. ap<0.001.186 J. NORDENBERG et al.
with sodium butyrate at a dose leading to a 40% decrease in
cell number in combination with several concentrations of
novobiocin resulted in a near additive growth inhibitory
effect (Figure 6).
The effect of combined treatment of the B16 cells with
novobiocin and either tiazofurin or mycophenolic acid is
depicted in Figures 7 and 8. The combination of novobiocin
with mycophenolic acid, or with tiazofurin resulted in a
decrease in cell number that was greater than the expected
calculated value of an additive interaction, suggesting that
novobiocin and GTP-depleting agents may interact synergis-
tically.
Discussion
Novobiocin was shown to induce anti-proliferative effects in
vitro and in vivo in B16 melanoma. Growth inhibition by
novobiocin was reversible and was accompanied by pheno-
typic alterations that resemble those induced by other
differentiating agents. These included morphological changes,
lipid droplet accumulation and enhancement of the activities
of NADPH cytochrome c reductase and glutamyl transpep-
tidase. We have previously shown that this specific pattern of
phenotypic alterations was induced by the well known chem-
ical inducer of differentiation sodium butyrate in mouse and
human melanoma cell lines (Nordenberg et al., 1986; 1987).
As previously suggested, the phenotypic alterations induced
by the differentiating agents are at least in part compatible
with a more differentiated state. The increase in NADPH
cytochrome c reductase, a marker enzyme of the endoplasmic
reticulum has been described to accompany the action of all
chemical inducers of differentiation that produced anti-pro-
liferative effects in melanoma cells (Fux et al., 1989). The
development of endoplasmic reticulum and the increase in its
marker enzyme (NADPH cytochrome c reductase) might
reflect cell differentiation, as normal melanocytic develop-
ment is also accompanied by the appearance of endoplasmic
reticulum and golgi complexes (Jimbo & Vesugi, 1982). A
potential role for y glutamyl transpeptidase in the synthesis
of pheomelanin from 5-S-cysteinyldopa has been suggested
(Mojamdar et al., 1983). Although novobiocin did not induce
a change in pigmentation similar to sodium butyrate, a
marked increase in the activity of this enzyme was observed.
Other melanoma differentiating agents, such as a MSH and
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Figure 7 Combined effects of novobiocin and tiazofurin on B16
melanoma cell growth. Cells (2 x 104 x 0.5 ml-') were incubated
for 72 h in the absence and presence of different tiazofurin and
novobiocin concentrations, alone and in combinations (A,B).
Values are means ± s.e. for 6-9 replicates done with different
cell preparations. The expected values for an additive interaction
were calculated as described in the Methods section. The
difference between the expected and obtained values was
significant P<0.01.
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Figure 8 Combined effects of novobiocin and mycophenolic acid
on B16 melanoma cell growth. Cells (2 x I04 x 0.5ml') were
incubated for 72 h in the absence and presence of different con-
centrations of mycophenolic acid and novobiocin, alone and in
combination. Values are means of 3-5 replicates ± s.d. of one
out of two experiments done with different cell preparations. The
expected values of an additive interaction were calculated as
described in the Methods section.
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Figure 6 The effect of combined addition of novobiocin
and sodium butyrate on B16 melanoma cell growth. Cells
(4 x 104 X ml') were incubated in the absence and presence of
sodium butyrate alone, novobiocin alone, or novobiocin +
sodium butyrate for 72 h. Values are means of six replicates done
with different cell preparations ± s.e. The expected values for an
additive interaction were calculated as described in the Methods
section.
theophylline were also reported to enhance the activity of this
enzyme (Hu, 1982; Mojamdar et al., 1983). In leukemic
HL-60 cells, the differentiating effect of novobiocin was
associated with a reduction in topoisomerase II activity
(Constantinou et al., 1989). Although similar concentrations
of novobiocin were effective on the melanoma cells, further
studies are required to link the anti-proliferative and
differentiating effects in the melanoma cells with decreased
+ 0.1
I
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topoisomerase II activity. Recent results obtained in our
laboratory indicate that novobiocin induces a moderate
decrease in ATP content of the cells (Novobiocin at
0.075 mM induced a decrease in intracellular ATP levels of
about 30%. The ATP content of untreated cells was
497 ± 57 nmoles mg-' DNA and of 0.075mM novobiocin-
treated cells was 357 ± 39 nmoles mg-' DNA). It is possible
that ATP depletion is related to the appearance of a more
differentiated phenotype. This suggestion is supported by our
previous findings (Fux et al., 1991).
Several combinations of differentiating agents with sodium
butyrate resulted in synergistic interactions. Novobiocin and
sodium butyrate were reported to have synergistic effects on
transformation of Chang liver cell into fibroblast-like cells
(Kaneko et al., 1988). These authors also found that novo-
biocin, similar to sodium butyrate increased nuclear protein
acetylation. The combined treatment of the B16 cells with
novobiocin and sodium butyrate did not result in a more
than additive interaction. This may suggest that these agents
act either independently on the cells, or by the same path-
way.
GTP-depleting agents, such as mycophenolic acid and tia-
zofurin were shown to be inducers of cell differentiation in
several cell types, including melanoma cells (Wright, 1987;
Sidi et al., 1988). Tiazofurin was also used in clinical trials
(Weber et al., 1989).
The mechanism for the combined synergistic interaction of
novobiocin and GTP-depleting agents has not been explored
so far. However, the decrease in both ATP and GTP might
provide a clue to the interaction of novobiocin and the
GTP-depleting agents. A methotrexate analog that depletes
ATP and GTP content has recently been reported to be a
potent inducer of leukaemic cell differentiation (Sokoloski et
al., 1990).
Previous studies of Eder et al. (1987; 1989) demonstrated
enhancement of the anti-tumour effects of alkylating agents
in leukaemia and fibrosarcoma bearing mice. In this study an
in vivo growth inhibitory effect of novobiocin was found in
melanoma bearing mice.
The mechanism of in vivo growth inhibition by novobiocin
is as yet unclear. The multiple targets that have been des-
cribed for the action of novobiocin (Gellert, 1982; Downes et
al., 1985; Lynch et al., 1976; Edenberg, 1980), do not identify
a specific mechanism. However, our data showing induction
of differentiation by novobiocin in vitro may imply that
phenotypic alterations occurring in vivo contribute to the
observed anti-tumour effect. The present study encourages
further investigation of the mechanism of the phenotypic
alterations induced by novobiocin in melanoma.
Novobiocin has a profound advantage over other
differentiating agents used so far, since it is a drug already
used as anti-microbial chemotherapy (Drusano et al., 1986).
This fact obviously facilitated the phase I trial with
novobiocin for solid tumours, including melanoma, that has
recently been reported (Eder et al., 1991).
This study was partially supported by the Schreiber Fund,
Tel-Aviv University.
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